Related Experiment Video

Updated: Jun 22, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Monoclonal antibodies for podocytopathies: rationale and clinical responses

Maddalena Marasà1, Jeffrey B Kopp

  • 1Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy.

Nature Reviews. Nephrology
|May 29, 2009
PubMed

Insights

Podocytopathies involve podocyte injury from various causes, potentially including immune system involvement. Biologic therapies targeting the immune system show promise but require further research for clear conclusions.

Area of Science:

  • Nephrology
  • Immunology
  • Pathology

Background:

  • Podocytopathies encompass diverse podocyte injuries like minimal-change nephropathy and focal segmental glomerulosclerosis.
  • Potential causes include genetic factors, infections, mechanical stress, medications, and likely immunologic injury.
  • Evidence suggests a role for immunologic injury in some podocytopathies, though mechanisms remain unclear.

Purpose of the Study:

  • To review the current understanding of podocytopathies and the emerging role of biologic therapies.
  • To explore the potential of immune-targeting agents in managing these kidney diseases.

Main Methods:

  • Review of existing literature on podocytopathies and their treatments.
  • Analysis of data from patients treated with biologic therapies, particularly rituximab.
  • Assessment of the current evidence for immunologic mechanisms in podocyte injury.

Main Results:

  • Biologic therapies targeting immune cells and cytokines are being used for various podocytopathies.
  • Rituximab is the most studied biologic agent in this context.
  • Current data are limited, hindering definitive conclusions about efficacy and mechanisms.

Conclusions:

  • While immunologic injury is suspected in some podocytopathies, precise pathways are not fully elucidated.
  • Biologic therapies offer a potential new treatment avenue, warranting further clinical investigation.
  • Continued research may clarify pathogenetic pathways and lead to novel therapeutic strategies for podocytopathies.

More Related Videos

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...